Scarica l'app Stockscreener
313.41
1.20%
-3.82
Dopo l'orario di chiusura:
312.82
-0.59
-0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$317.23
Aprire:
$319
Volume 24 ore:
824.66K
Relative Volume:
0.54
Capitalizzazione di mercato:
$41.57B
Reddito:
$3.71B
Utile/perdita netta:
$313.75M
Rapporto P/E:
138.86
EPS:
2.2571
Flusso di cassa netto:
$465.38M
1 W Prestazione:
-2.26%
1M Prestazione:
-0.31%
6M Prestazione:
-32.73%
1 anno Prestazione:
+29.64%
Intervallo 1D:
$309.92
$319.50
Intervallo di 1 settimana:
$309.61
$326.18
Portata 52W:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
JP Morgan Maintains Alnylam Pharmaceuticals (ALNY) Overweight Recommendation - MSN
How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story - simplywall.st
Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits - JD Supra
siRNA Therapeutics Market Poised for Rapid Growth to US$ 12.38 - openPR.com
Why Alnylam Pharmaceuticals Stock Was Soaring on Monday - AOL.com
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Atika Capital Management LLC - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Lifted by WINTON GROUP Ltd - MarketBeat
Legal & General Group Plc Has $404.83 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How Investors May Respond To Alnylam (ALNY) Expanding Cardiovascular RNAi Targets Through Tenaya Collaboration - simplywall.st
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
Capital Research Global Investors Boosts Holdings in Alnylam Pharmaceuticals - National Today
Alnylam to Webcast TTR Investor Webinar - Business Wire
Capital Research Global Investors Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Capital World Investors - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Raised by Capital International Inc. CA - MarketBeat
Swiss National Bank Has $171.37 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Holdings Raised by Jefferies Financial Group Inc. - MarketBeat
Alnylam Pharmaceuticals grants performance-based equity award to CEO - Investing.com Nigeria
12,658 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Fieldview Capital Management LLC - MarketBeat
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam nabs key additional indication for Amvuttra - MSN
Alnylam targets 25% revenue CAGR through 2030 amid AMVUTTRA launch momentum and pipeline expansion - MSN
Korea Investment CORP Grows Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Rhenman & Partners Asset Management AB Has $14.54 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics - simplywall.st
Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation - Yahoo Finance
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - Yahoo Finance
ALNYLAM PHARMACEUTICALS Executives Sell Shares - TradingView
Alnylam (NASDAQ: ALNY) CEO sell-to-cover 2,933 shares for tax withholding - Stock Titan
Tax-withholding stock sale for Alnylam (ALNY) EVP disclosed - Stock Titan
Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After Recent Share Price Pullback - simplywall.st
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - bioworld.com
Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam - The Pharma Letter
Victory Capital Management Inc. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal - Pharmaceutical Technology
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - Yahoo Finance
Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Sahm
Alnylam Updates Hypertension Pipeline And AMVUTTRA Access Shape Valuation View - Sahm
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Responsive Playbooks and the ALNY Inflection - Stock Traders Daily
Tenaya To Evaluate Genetic Cardiovascular Targets For Alnylam - Citeline News & Insights
Alnylam board creates $18M incentive award to keep CEO through 2029 - The Business Journals
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - Investing News Network
Tenaya wins support from Alnylam in cardio disease pact - Endpoints News
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - marketscreener.com
Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam - marketscreener.com
Alnylam Pharmaceuticals (ALNY) Forms Partnership for Cardiovascu - GuruFocus
Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development - PR Newswire
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration - TipRanks
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - Seeking Alpha
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):